Information Provided By:
Fly News Breaks for September 23, 2015
PCRX, HRTX
Sep 23, 2015 | 06:51 EDT
Jefferies analyst Biren Amin raised his price target for Heron Therapeutics (HRTX) to $58 saying last night's Phase II results show "robust reduction" in pain intensity. The analyst believes the data compares favorably versus Pacira's (PCRX) Exparel. He keeps a Buy rating on Heron.
News For HRTX;PCRX From the Last 2 Days
There are no results for your query HRTX;PCRX